Figure 4A demonstrates significantly restored NK cell-based cytotoxicity against cetuximab-coated HNSCC cells with mAb concentrations of 1 μg/ml (mean: 43.8 ± 10.8%) and 1 ng/ml (mean: 38.4 ± 6.8%) as compared to reduced killing activity of shMICA-incubated NK cells (mean: 13.4 ± 11.2%) against non-coated HNSCC cells and anti-CD16 mAb-blocked NK cells (mean: 28.8 ± 8.9%). This evidence concerns the gene FCGR3A and head and neck squamous cell carcinoma.